0.2780SEK-11.46%Mkt Cap: 17.63M SEKP/E: —Last update: 2026-05-13
Stayble Therapeutics AB (publ) a clinical pharmaceutical company, developing an injection-based treatments for disc herniation. It develops STA363, an injection into the disc that targets chronic low back and leg pain. T…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
P/B2.54
P/S375.20
EV/EBITDA—
EV/Revenue341.12
EPS (TTM)-0.12
EPS (Forward)—
Cash Flow & Leverage
FCF Yield-23.68%
FCF Margin-8884.33%
Operating CF-6.72M SEK
CapEx (TTM)—
Net Debt/EBITDA—
Net Debt-1.60M SEK
Technical
SMA 500.1566 (+77.6%)
SMA 2000.2264 (+22.8%)
Beta-0.88
S&P 52W Chg24.23%
Avg Vol (30d)6.07M
Avg Vol (10d)15.19M
Technical Indicators
RSI (14)64.6
MACD0.0394
MACD Signal0.0053
MACD Hist.+0.0341
BB Upper0.3720 SEK
BB Middle0.1235 SEK
BB Lower-0.1249 SEK
BB Width402.16%
ATR (14)0.0753 SEK
Vol Ratio (20d)0.25x
52W Range
0.027441% of range0.6460
52W High0.6460 SEK
52W Low0.0274 SEK
Profitability
Gross Margin100.00%
EBITDA Margin0.00%
Profit Margin0.00%
Oper. Margin-14836.17%
ROE-100.09%
ROA-80.36%
Revenue Growth—
Earnings Growth—
Balance Sheet
Debt/Equity12.28
Current Ratio3.50
Quick Ratio3.16
Book Value/Sh0.1080 SEK
Cash/Share0.0380 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.64.36M
Float56.45M
Insiders21.52%
Institutions21.41%
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Company
Market Cap17.63M SEK
Enterprise Value16.03M SEK
Revenue (TTM)47.00K SEK
Gross Profit47.00K SEK
Net Income (TTM)-6.93M SEK
Revenue/Share0.0010 SEK
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees2
Last Price0.2780 SEK
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—